Hepta released proof‑of‑concept data showing cell‑free DNA methylation patterns in plasma reflect liver tissue biology and fibrosis states. The company built a multiomic liver atlas with single‑cell and bulk gene expression, chromatin accessibility and methylation, then demonstrated concordant signals in cfDNA. Hepta argues methylation‑based cfDNA tests can noninvasively report pathway activity and cell‑type composition in liver disease, offering a potential alternative to protein biomarkers and liver biopsy for diagnosing and staging MASH/NASH and fibrosis.